Ovarian Cancer Portfolio Analysis: Over 100 Companies Are Working to Improve the Treatment Space | DelveInsight

Ovarian Cancer Portfolio Analysis: Over 100 Companies Are Working to Improve the Treatment Space |  DelveInsight
Ovarian Cancer Portfolio Analysis: Over 100 Companies Are Working to Improve the Treatment Space |  DelveInsight

DelveInsight, “Ovarian Cancer Channeling Outlook, 2022”, the report provides detailed information on more than 100 companies and more than 100 drugs in development in the ovarian cancer development landscape. Covers profiles of drugs in development, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration, and molecule type. It further highlights idle piping products in this space.

Key Points from the Ovarian Cancer Pipeline Outlook Report

  • by DelveInsight Ovarian cancer The Pipeline report outlines a robust space with more than 100 active players working to develop more than 100 pipeline therapies for Ovarian cancer.
  • Leader Ovarian cancer Companies such as Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion and others are developing potential drug candidates to improve ovarian function . Cancer treatment scenario.
  • Promising Ovarian Cancer Therapies Like Atezolizumab, Tisotumab Vedotin, Pembrolizumab and Others

Get an overview of the pipeline landscape @ Ovarian Cancer Clinical Trial Analysis

Ovarian Cancer Overview

Ovarian cancer is a type of cancer that begins in a woman’s ovaries, the small organs of the female reproductive system that create eggs. This type of cancer can be difficult to detect because it often does not cause any symptoms until later stages. Once found, ovarian cancer can be treated with chemotherapy and surgery to remove any tumors. As with most cancers, ovarian cancer becomes more common as a person ages. The risk of ovarian cancer increases considerably after the age of 45 and is greatest between the ages of 75 and 79. Between 5 and 15 out of 100 ovarian cancers (5 to 15%) are caused by an inherited faulty gene. Inherited genes that increase the risk of ovarian cancer include defective versions of BRCA1 and BRCA2. Faults in these genes also increase the risk of breast cancer.

Recent Advances in the Ovarian Cancer Treatment Landscape

  • In May 2021, On Target Laboratories, Inc. announced the results of Study 006, a phase 3, randomized, multicenter, prospective, open-label study to study the safety and efficacy of pafolacianin sodium injection (OTL38) in obtaining Intraoperative imaging of folate receptor-positive ovarian cancer.
  • In April 2021, Shenzhen Chipscreen Biosciences announced that it had received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) to proceed with a Phase 1b/2 clinical trial of Chiauranib/CS2164, a potential treatment for oncological indications, including small cell lung cancer (SCLC), ovarian cancer, liver cancer, and breast cancer, etc. phases of clinical studies.
  • Stenoparib (2X-121) is a unique small-molecule dual-target inhibitor of poly ADP-ribose polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity was exclusively licensed (worldwide) from Eisai. It is currently in Phase II trials for ovarian cancer with patients selected by Stenoparib DRP.
  • In June 2021, Apexigen, Inc., a clinical-stage biopharmaceutical company, focused on discovering and developing a new generation of antibody therapies for oncology. The Nordic Society of Gynecologic Oncology – Clinical Trials Unit (NSGO-CTU) declared an agreement to initiate a collaborative Phase 2 clinical study evaluating sotigalimab, Apexigen’s anti-CD40 monoclonal antibody, in combination therapy for patients with ovarian cancer recurrent BRCA wild-type. Sotigalimab, Apexigen’s leading immuno-oncology therapeutic candidate, is a potentially first-in-class and best-in-class CD40 agonist with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect and tolerability.
  • VBL Therapeutics’ lead oncology product candidate, VB-111 (ofranergene obadenovec), is a targeted anti-cancer gene-based biologic agent positioned to potentially treat a wide range of solid tumors. VB-111 has been shown to be well-tolerated in >300 cancer patients in an “all interested” phase 1 trial, as well as three tumor-specific phase 2 studies for ovarian cancer, recurrent glioblastoma (rGBM) and thyroid cancer. VB-111 is currently being studied in the phase 3 OVAL study for platinum-resistant ovarian cancer.

For more information, see the detailed report @ Channeling therapy for ovarian cancer

Emerging medicines for ovarian cancer

  • Atezolizumab: Genentech
  • Tisotumab vedotin: Genmab
  • Pembrolizumab: Merck

DelveInsight’s Ovarian Cancer Pipeline report covers more than 100 products in different phases of clinical development, such as

  • Late-stage products (Phase III)
  • Intermediate stage products (Phase II)
  • Early stage product (Phase I) along with details of
  • Preclinical and Discovery Stage Candidates
  • Discontinued and inactive candidates
  • Administration route

Learn more about ovarian cancer medications @ Ovarian Cancer Treatment

Scope of the Ovarian Cancer Pipeline Report

  • Coverage- Global
  • Ovarian cancer Companies: Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion and others
  • Ovarian cancer Therapies: atezolizumab, tisotumab vedotin, pembrolizumab, and others

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Ovarian Cancer: Overview
  4. pipeline therapeutics
  5. Therapeutic Assessment
  6. Ovarian Cancer: DelveInsight Analytical Perspective
  7. Deep Business Assessment
  8. Collaboration Offers for Ovarian Cancer
  9. Late-stage products (Phase III)
  10. Atezolizumab: Genentech
  11. Intermediate Stage Products (Phase II)
  12. Tisotumab vedotin: Genmab
  13. inactive products
  14. Key Ovarian Cancer Companies
  15. Key products for ovarian cancer
  16. Ovarian cancer: unmet needs
  17. Ovarian Cancer: Market Drivers and Barriers
  18. Ovarian Cancer: Future Perspectives and Conclusion
  19. Ovarian Cancer Analyst Opinions
  20. Key Ovarian Cancer Companies
  21. Appendix

Dive into valuable information on medications for the treatment of ovarian cancer, visit @ New drug for the treatment of ovarian cancer

Media contact
Company Name: DelveInsight Business Research LLP
Contact person: Yash Bhardwaj
Email: Send an e-mail
Telephone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
Condition: Snowfall
Country: USA
Website: https://www.delveinsight.com/

Leave a Comment